ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0955

Unfavorable Pregnancy Outcome Is Significantly Associated with Corticosteroid Exposure During Pregnancy in Women with RA: Analysis of the Prospective GR2 Cohort

SABRINA HAMROUN1, Marion Couderc2, Rene-Marc Flipo3, Laure Gossec4, Christophe Richez5, Rakiba Belkhir6, Aline Frazier-Mironer7, Valerie Devauchelle8, Hubert Marotte9, Jérémie SELLAM10, elisabeth gervais11, Alban DEROUX12, Cédric Lukas13, Emmanuelle Dernis14, Emmanuel Chatelus15 and Anna Molto16, 1Rheumatology Department, University Hospital of Cochin, Paris, Paris, France, 2University Hospital, Clermont-Ferrand, France, 3CHU Lille, Boulogne-Billancourt, France, 4Sorbonne Université, Paris, France, 5Université de Bordeaux, Bordeaux, France, 6Rheumatology departement, Bicêtre, Paris-Saclay university, Le Kremlin Bicêtre, France, 7APHP Hôpital Lariboisire, Paris, France, 8Université de Bretagne Occidentale, Brest, France, 9INSERM 1059, Saint-Etienne, France, 10Sorbonne Universite, AP-HP, Saint-Antoine hospital, Paris, France, 11chu poitiers, Poitiers, France, 12CHU Grenoble, Grenoble, France, 13University Hospital Centre Montpellier, University of Montpellier, Montpellier, France, 14LE MANS general hospital, LE MANS, France, 15University Hospital of Strasbourg, Strasbourg, France, 16Rheumatology Department, Cochin Hospital, APHP, Paris, France

Meeting: ACR Convergence 2022

Keywords: glucocorticoids, pregnancy, rheumatoid arthritis

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 13, 2022

Title: Reproductive Issues in Rheumatic Disorders Poster

Session Type: Poster Session B

Session Time: 9:00AM-10:30AM

Background/Purpose: Rheumatoid arthritis (RA) is one of the most common chronic inflammatory diseases and regularly affects women of childbearing age. However, there is limited knowledge about the impact of the disease and its treatment on pregnancy. The aim of the study was to determine the factors associated with adverse pregnancy outcome in women with RA.

Methods: All RA patients (diagnosis according to the Rheumatologist) included in the national multicenter GR2 cohort from 2015 to June 2021 were included in the analysis. Patients could be included either with a pregnancy wish (i.e., preconceptional period) or because of a clinical pregnancy (< 12 weeks of gestation). The main endpoint was favorable pregnancy outcome, a composite outcome defined as a live birth at term ≥ 37 gestation weeks of a healthy newborn with a weight greater than the 10th percentile. Disease activity was defined by a DAS28-CRP score > 3.2 at least once during pregnancy. We performed a multilevel logistic regression model, in which we considered patient and center random effects (patient random effect for some women included in the cohort two times). We used a multiple imputation procedure to address missing data among the explanatory variables. Results are presented as an odds ratio (OR) with confidence interval (CI).

Results: Among the 167 pregnancies in women with RA included in the GR2 cohort, 92 were retained for analysis of obstetrical outcome. Of these, 43 (46.2%), 8 (7.9%), 40 (43.5%) were exposed to corticosteroid, NSAID and biologics at least once during pregnancy, respectively. A moderate or severe disease activity at least once during pregnancy was found in 20 (21.8%) pregnancies. A live birth was found in 83 (90.2%) women, including 69 (83.1%) full-term births. Early miscarriages were observed in 9 (0.1%) women. A caesarean section was performed in 22 (23.9%) cases. A favorable pregnancy outcome was found in 52 (56.5%) of the women. Unfavorable pregnancy outcome was mainly due to prematurity and small for gestational age, observed in 14 (16.9%) and 17 (20.5%), respectively. The multivariate model adjusted for age, BMI, nulliparity, active disease during pregnancy, smoking, and exposure to biologics and corticosteroids during pregnancy found an association between an unfavorable pregnancy outcome and nulliparity (OR 6.2 95% CI [2.1-17.8] p = 0.002), age (OR (per year) 1.1 95% CI [1.0-1.3] p = 0.02) and exposition to corticosteroids during pregnancy (OR 3.2 95% CI [1.1-9.6] p = 0.04).

Conclusion: This study provides original results on pregnancy in women with RA. It found a favorable pregnancy outcome in 56.5% of women. Unfavorable pregnancy outcome was associated with age, nulliparity and corticosteroids use during pregnancy, which argues for their careful use during pregnancy.

Supporting image 1


Disclosures: S. HAMROUN, None; M. Couderc, None; R. Flipo, Merck/MSD, Novartis, Janssen; L. Gossec, Amgen, Lilly, Pfizer, Sandoz, UCB Pharma, AbbVie, Bristol Myers Squibb, Gilead, Janssen, Novartis, Samsung Bioepis, Sanofi-Aventis, Galapagos, GlaxoSmithKlein (GSK), Celltrion, MSD; C. Richez, AbbVie/Abbott, Amgen, AstraZeneca, Biogen, Bristol-Myers Squibb(BMS), Galapados, GlaxoSmithKlein(GSK), Eli Lilly, Novartis, Pfizer; R. Belkhir, None; A. Frazier-Mironer, None; V. Devauchelle, Pfizer, Novartis, AbbVie/Abbott, Novartis, Bristol-Myers Squibb(BMS), Roche-Chugai, Galapados; H. Marotte, AbbVie/Abbott, Amgen, Biogen, Bristol-Myers Squibb(BMS), CellTrion HealthCare, Fresenius Kabi, HealthCare, Janssen, Eli Lilly, Nordic Pharma, Novartis, Medac, Pfizer, Merck/MSD, Galapagos, UCB; J. SELLAM, None; e. gervais, None; A. DEROUX, None; C. Lukas, None; E. Dernis, AbbVie/Abbott, Amgen, Bristol-Myers Squibb(BMS), Janssen, Nordic Pharma France, Novartis, UCB; E. Chatelus, None; A. Molto, None.

To cite this abstract in AMA style:

HAMROUN S, Couderc M, Flipo R, Gossec L, Richez C, Belkhir R, Frazier-Mironer A, Devauchelle V, Marotte H, SELLAM J, gervais e, DEROUX A, Lukas C, Dernis E, Chatelus E, Molto A. Unfavorable Pregnancy Outcome Is Significantly Associated with Corticosteroid Exposure During Pregnancy in Women with RA: Analysis of the Prospective GR2 Cohort [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/unfavorable-pregnancy-outcome-is-significantly-associated-with-corticosteroid-exposure-during-pregnancy-in-women-with-ra-analysis-of-the-prospective-gr2-cohort/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/unfavorable-pregnancy-outcome-is-significantly-associated-with-corticosteroid-exposure-during-pregnancy-in-women-with-ra-analysis-of-the-prospective-gr2-cohort/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology